Overview

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Status:
Active, not recruiting

Trial end date:
2022-09-27

Target enrollment:

Participant gender:

Summary

This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety and pharmacokinetics of orally administered venetoclax (ABT-199) combined with decitabine or azacitidine and the preliminary efficacy of these combinations. In addition, there is a drug-drug interaction (DDI) sub-study only at a single site, to assess the pharmacokinetics and safety of venetoclax (ABT-199) in combination with posaconazole.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Collaborator:

Genentech, Inc.

Treatments:

Azacitidine
Decitabine
Posaconazole
Venetoclax